Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06801236 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06801236 · ClinicalTrials.gov record · last posted 2026-08-04

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

StatusRecruiting
PhasePhase 1
Started2025-05-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Protocol amendment history 3 changes detected by DataLookout

2026-08-05
Enrollment increased: 67 → 88 participants
2026-08-05
Primary completion pushed: 2028-03-01 → 2028-12-31
2026-08-05
Completion pushed: 2028-08-01 → 2028-12-31
Trial Details
NCT Number NCT06801236
Lead Sponsor Acerand Therapeutics (Hong Kong) Limited
Conditions Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Enrollment 88 participants
Start Date 2025-05-12
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-04